Gentamicin: Nursing Drug Guide, Nephrotoxicity & Trough Monitoring
Parenteral aminoglycoside for serious gram-negative infections: the bedside priority is cumulative nephrotoxicity and eighth cranial nerve ototoxicity—often irreversible—when mg/kg errors, prolonged peaks or troughs, renal impairment, or concurrent potent diuretics such as furosemide go unchecked. Verify weight-based dosing, dilute and infuse IV gentamicin correctly, draw peak/trough levels on schedule, and trend creatinine, urine output, and new tinnitus or vertigo every shift.
Labeling warns that gentamicin can cause nephrotoxicity and ototoxicity affecting vestibular and auditory eighth cranial nerve function—damage is usually irreversible. Monitor renal function and auditory/vestibular status closely. Avoid prolonged peak concentrations above 12 mcg/mL and trough above 2 mcg/mL. Avoid concurrent nephrotoxic or ototoxic drugs and potent diuretics (furosemide, ethacrynic acid). Gentamicin can cause fetal harm when used in pregnancy.
📋 Contents
⚡ Quick facts
💡 Key takeaway
Before every dose, verify mg/kg against current weight, review the latest basic metabolic panel and eGFR, and confirm trough timing with pharmacy. Hold gentamicin when creatinine rises sharply, urine output falls, trough exceeds protocol limits, or the patient reports new tinnitus—then notify the prescriber or pharmacist. Pair therapy with accurate intake and output monitoring and high-alert medication administration double-checks.
Most common brand names
Garamycin is a recognized brand for gentamicin sulfate injection. Generic gentamicin is widely available as IV/IM injection (commonly 10 mg/mL and 40 mg/mL concentrations). Topical gentamicin products exist for ophthalmic or dermatologic use—these are separate formulations from systemic injectable therapy; do not substitute without prescriber and pharmacy direction.
Verify concentration (mg/mL), total mg/kg/day, and interval on every pass—aminoglycoside regimens are weight-based and frequently adjusted when renal function changes.
Why we give it — Indications
Gentamicin is a bactericidal aminoglycoside used for serious infections caused by susceptible gram-negative organisms. Nurses most often see it during inpatient treatment of sepsis, pneumonia, and meningitis when culture data or local antibiograms support aminoglycoside therapy—often combined with beta-lactams or vancomycin for synergy or broader coverage.
| Use | Detail |
|---|---|
| Serious gram-negative infections | Include sepsis, pneumonia, urinary tract, bone/joint, and intra-abdominal infections when susceptible organisms identified or strongly suspected |
| Combination therapy | Often paired with a cell-wall agent; obtain blood cultures before antibiotics when clinically feasible |
| Duration | Usually 7–10 days per labeling; reassess need for continued aminoglycoside exposure |
On a small screen, swipe or scroll sideways to see the full table.
Monitor for persistent fever or clinical instability despite appropriate gram-negative coverage—may signal need for regimen change rather than automatic dose escalation.
How it works
Gentamicin binds the 30S ribosomal subunit and disrupts bacterial protein synthesis, producing concentration-dependent bactericidal activity against many aerobic gram-negative bacilli. Because aminoglycosides penetrate poorly into some tissues and require active renal clearance, tissue levels and serum concentrations must be monitored—especially when renal perfusion drops or concurrent nephrotoxic drugs are on the MAR.
Renal proximal tubular uptake concentrates gentamicin in kidney cells, which explains dose- and duration-related nephrotoxicity. Cochlear and vestibular hair cells are similarly vulnerable, producing auditory and vestibular toxicity that labeling states is usually irreversible.
Dosing overview
Individualize to infection severity, renal function, and pharmacy protocol. Labeling emphasizes weight-based dosing and renal adjustment—never copy a neighbor patient’s mg dose without recalculating mg/kg.
Hemodialysis: Removes approximately 50% of gentamicin in 8 hours per labeling—coordinate post-dialysis dosing with pharmacy.
Missed dose: Not specified in the reviewed prescribing information; follow prescriber or pharmacy guidance and do not double doses without authorization.
Onset, peak, and duration
- IV: Serum levels depend on infusion completion time—document stop time for peak/trough coordination
- Peak/trough targets: Labeling warns against prolonged peaks >12 mcg/mL and troughs >2 mcg/mL because toxicity risk rises
- Half-life: Prolonged in renal impairment—interval extension often required as creatinine rises
- Duration of therapy: Usually 7–10 days; longer courses increase cumulative nephro- and ototoxicity risk
- Dialysis: Significant removal with hemodialysis—pharmacy typically redoses after dialysis per protocol
Before you give it — Safety check
Pretreatment checks
- Current weight and calculated mg/kg/day versus MAR order—independent double-check with pharmacy when possible
- Latest BMP: creatinine, BUN, electrolytes; trend eGFR across the admission
- Allergy history to gentamicin or other aminoglycosides (cross-sensitivity possible)
- Concurrent nephrotoxic or ototoxic drugs—especially loop diuretics such as furosemide, vancomycin, amphotericin, or other aminoglycosides
- Whether trough or peak draw is due before the next scheduled dose
Contraindications
- Hypersensitivity to gentamicin
- Serious toxic reaction to another aminoglycoside (potential cross-sensitivity per labeling)
Important interactions
| Drug / class | Effect | Nursing action |
|---|---|---|
| Potent diuretics (furosemide, ethacrynic acid) | Boxed warning: increased nephrotoxicity and ototoxicity—avoid concurrent use when possible | Trend creatinine and urine output; assess for tinnitus/vertigo; involve pharmacy early |
| Other nephrotoxic drugs | Additive renal injury with vancomycin, amphotericin, cisplatin, NSAIDs | Monitor BMP at least daily during therapy; hold and notify for sharp creatinine rise |
| Neuromuscular blocking agents | May prolong neuromuscular blockade | Coordinate with anesthesia/ICU for ventilated patients |
| Other ototoxic drugs | Increased auditory/vestibular injury risk | Baseline and ongoing symptom assessment; document new tinnitus immediately |
On a small screen, swipe or scroll sideways to see the full table.
Administration
IV: Gentamicin injection must be diluted before administration. For adults, use 50–200 mL of compatible diluent and infuse over 30 minutes to 2 hours per labeling. Do not premix with other drugs in the same container.
- Verify mg/kg, concentration (mg/mL), and total volume with an independent double-check
- Use IV medication administration best practice: dedicated line or proper flush sequence when sharing access
- Document infusion start and stop times—critical for peak/trough interpretation
- IM: May be given undiluted deep IM when IV access unavailable; rotate sites
Rapid infusion or concentration errors increase renal tubular exposure and toxicity risk. Never bolus undiluted IV gentamicin unless a specific protocol explicitly directs it—and even then follow pharmacy guidance. Pair administration with medication reconciliation at transitions so home or duplicate aminoglycoside orders do not stack silently.
Expected therapeutic response
- Defervescence and hemodynamic stabilization in sepsis when organism is susceptible
- Improving white blood cell trend and clinical source control (e.g., clearer lungs, controlled urine source)
- Culture and sensitivity data supporting continued aminoglycoside use
- Therapeutic drug levels within pharmacy target range without rising creatinine or auditory symptoms
Red flags — Stop and act
Aminoglycoside toxicity can progress while the patient still appears hemodynamically stable—do not wait for dialysis-level renal failure before escalating.
- Creatinine or BUN rising sharply across serial BMP values—possible acute kidney injury
- Oliguria or urine output falling despite adequate perfusion
- New tinnitus, hearing loss, or vertigo—may indicate irreversible eighth cranial nerve injury
- Trough above 2 mcg/mL or peak prolonged above 12 mcg/mL per labeling thresholds
- Concurrent potent diuretic on the MAR with accelerating renal decline
- Hypersensitivity reaction, severe rash, or bronchospasm
Adverse effects
| Adverse effect | Notes (labeling) | Nursing response |
|---|---|---|
| Nephrotoxicity | Boxed warning; related to dose, duration, and concurrent nephrotoxins | Trend creatinine/BUN and urine output; hold and notify for acute rise |
| Ototoxicity | Auditory and vestibular eighth cranial nerve damage—usually irreversible | Document tinnitus/hearing changes immediately; involve prescriber and audiology per protocol |
| Neurotoxicity | Numbness, skin tingling, muscle twitching, seizures (rare) | Neurologic assessment; hold and escalate per prescriber direction |
| Hypersensitivity | Rash, drug fever, anaphylaxis reported | Stop infusion; follow anaphylaxis protocol per facility policy |
| Neuromuscular blockade | May aggravate blockade with concurrent neuromuscular blockers | Monitor respiratory status in ventilated patients |
| Laboratory abnormalities | Non-renal azotemia, anemia, thrombocytopenia reported | Review CBC and BMP trends with pharmacy |
On a small screen, swipe or scroll sideways to see the full table.
Whenever adverse reactions are moderate or severe, gentamicin dosage should be reduced or therapy withdrawn per labeling and prescriber direction.
Overdose, toxicity, and antidote
Principal signs of overdose or excessive exposure reflect exaggerated aminoglycoside toxicity: renal dysfunction, auditory and vestibular injury, and neuromuscular weakness in severe cases.
Antidote
Not specified in the reviewed prescribing information — there is no listed specific reversing agent. Treatment is supportive.
Management per labeling
- Hold or adjust therapy with prescriber and pharmacy input
- Monitor renal function, fluid status, and neurologic/auditory symptoms closely
- Hemodialysis may aid removal—approximately 50% removed in 8 hours per labeling
- Contact local poison control or medical toxicology services per facility protocol for significant overdose or instability
Look-alike / sound-alike and error prevention
- Gentamicin vs tobramycin vs amikacin — all aminoglycosides but not interchangeable; verify drug name, mg/kg/day, and interval on every pass
- Garamycin brand name — verbal orders may be misheard; confirm generic name and total milligrams in writing
- 10 mg/mL vs 40 mg/mL vials — triple-check concentration before drawing dose; use leading zeros per institutional policy
- mg vs mg/kg — most errors occur when a total mg dose is copied without weight recalculation
- Duplicate aminoglycoside therapy — home or prior-facility orders may persist; perform medication reconciliation at every transition
Practical bedside notes
| Topic | Bedside guidance |
|---|---|
| Trough timing | Draw within 30 minutes before next dose per pharmacy protocol; notify lab if dose delayed |
| Infusion documentation | Record exact stop time—peaks are interpreted from infusion completion |
| Dilution volume | Adults: 50–200 mL compatible diluent; infuse 30 min–2 h |
| Line management | Do not premix with other drugs; follow compatibility chart for Y-site if used |
| Auditory checks | Ask about tinnitus each shift; baseline whisper or finger-rub test if protocol allows |
| Ask pharmacy when | Renal function changes, missed doses, dialysis timing, out-of-range levels, or unclear mg/kg calculation |
On a small screen, swipe or scroll sideways to see the full table.
High-risk populations
| Population | Considerations |
|---|---|
| Older adults | Reduced renal reserve increases nephrotoxicity risk; lower baseline creatinine may mask injury—trend eGFR and urine output |
| Renal impairment | Requires interval extension or dose reduction; hemodialysis removes drug—coordinate redosing |
| Dehydration / hypotension | Reduced renal perfusion raises tubular gentamicin concentration |
| Pregnancy | Boxed warning: fetal harm; use only if potential benefit justifies risk |
| Lactation | LactMed notes poor excretion into breast milk but advises monitoring infant GI flora if used |
| Neonates and infants | Immature renal function prolongs half-life—use neonatal dosing tables and level monitoring |
| Concurrent diuretics | Potent loop diuretics increase nephro- and ototoxicity—avoid when possible per boxed warning |
On a small screen, swipe or scroll sideways to see the full table.
Monitoring and documentation
Monitor
- Serum creatinine, BUN, and eGFR—at least daily during therapy; more often if declining
- Peak and trough gentamicin levels per pharmacy protocol; avoid trough >2 mcg/mL and prolonged peak >12 mcg/mL
- Urine output and net fluid balance each shift
- Auditory symptoms (tinnitus, hearing loss) and vestibular symptoms (vertigo, imbalance)
- Signs of neuromuscular weakness when neuromuscular blockers are co-administered
Document
- Weight used for mg/kg calculation, total dose, dilution volume, infusion start/stop times
- Level draw times relative to scheduled doses
- Creatinine trend and any hold parameters triggered
- Patient teaching on reporting tinnitus, hearing changes, and decreased urination
Patient teaching
- Report ringing in the ears, hearing loss, dizziness, or balance problems immediately—these may indicate permanent injury
- Notify the nurse if urination decreases or you feel more swollen or short of breath
- IV gentamicin requires the full infusion time—do not ask staff to speed the pump
- Tell your care team about all medicines including OTC pain relievers and herbal products
- Understand that blood draws for drug levels are part of safe therapy—not optional extras
- Ask when to follow up for hearing assessment if aminoglycoside therapy was prolonged
The Hold Rule
Do not give and contact the prescriber/pharmacist when:
- Known gentamicin allergy or serious aminoglycoside hypersensitivity
- Sharp creatinine or BUN rise suggesting nephrotoxicity
- Oliguria or inadequate urine output without prescriber-directed plan
- Trough above 2 mcg/mL or peak prolonged above 12 mcg/mL until pharmacy/prescriber adjusts regimen
- New tinnitus, hearing loss, or vertigo during therapy
- Unable to verify correct mg/kg dose, dilution, or infusion rate
Hold parameters may vary by institutional protocol. Follow prescriber orders, pharmacy guidance, and facility policy.
Clinical practice integration and workflow
Gentamicin saves lives in serious gram-negative sepsis—but it is also one of the most predictable sources of preventable renal and auditory injury when nurses treat infusions as routine without trending levels and creatinine.
1. Check-before-you-give protocol
- Right patient, drug, mg/kg dose, dilution, route, time—and right renal labs within acceptable timeframe
- Compare today’s weight to admission weight; recalculate if change exceeds protocol threshold
- Confirm trough/peak draw status with pharmacy before hanging the bag
- Scan MAR for furosemide, vancomycin, and duplicate aminoglycosides
2. High-alert and safety badge
Not on every institutional high-alert list, but boxed-warning aminoglycoside — independent verification of mg/kg, dilution, and renal status recommendedBoxed warning emphasizes nephrotoxicity and usually irreversible ototoxicity with peak/trough and renal monitoring required.
3. Clinical workflow: hold and question rules
- If creatinine rises across two BMP values, hold the next dose and page pharmacy before hanging another infusion
- If urine output drops while gentamicin continues, clarify whether infection is improving or kidneys are failing
- Never shorten infusion time for convenience—documented stop time drives level interpretation
4. Critical teach-back questions
- “What new symptoms should you report while on this antibiotic?” (Patient should name ringing in the ears, hearing loss, dizziness, or decreased urination.)
- “Why will staff draw blood before some doses?” (Patient should describe drug-level monitoring to keep the medicine effective and safe for kidneys and hearing.)
5. Care coordination
Pharmacist: mg/kg verification, renal dose adjustment, peak/trough scheduling, dialysis redosing, and interaction review with diuretics and vancomycin
Prescriber: Notify for rising creatinine, out-of-range levels, new auditory symptoms, or need to narrow/de-escalate gram-negative coverage
🧠 Quick mental checklist
- What is today’s weight-based mg/kg dose—and who double-checked it?
- Is creatinine trending up or urine output falling?
- Is a trough due before this dose—and was the last level therapeutic?
- Are furosemide or other nephrotoxins still on the MAR?
- Did I ask about new tinnitus, hearing loss, or vertigo this shift?
Gentamicin NCLEX practice questions
Rehearse NCLEX-style clinical judgment practice for gentamicin using a tabbed sepsis case (MAR, labs, I&O, nursing notes), then priority action, cue recognition SATA, renal trend SATA, matrix urgency sorting, IV dilution judgment, and toxicity cloze—with explicit evaluate outcomes items after therapy adjustment.
Select a tab to view MAR, labs, I&O, and nursing note details for this case.
- Gentamicin 140 mg IV q12h (70 kg = 4 mg/kg/day) — due 1400; pharmacy note: trough before dose
- Furosemide 40 mg IV q12h — given 0800
- Vancomycin 1 g IV q12h — due 1800
- Normal saline IV at 75 mL/h
- Piperacillin-tazobactam 3.375 g IV q6h — per sepsis protocol
- Creatinine 1.0 → 1.5 → 2.1 mg/dL over 72 h (BMP 0730)
- BUN 18 → 28 → 42 mg/dL
- Yesterday gentamicin trough 3.8 mcg/mL (pharmacy comment: above target)
- WBC trending down; blood cultures pending final identification
- Urine output 68 mL/h average yesterday → 35 mL/h last 8 h (Foley)
- Intake 2.4 L; net even to slightly positive
- Blood pressure improved: 104/62 (was 88/52 on admission)
- 78-year-old admitted for sepsis secondary to pneumonia; day 4 of gentamicin
- 0900: patient reports new bilateral ringing in ears since overnight
- 1100: prior dose infused in 50 mL over 20 minutes—stop time documented 2210
- 1300: nurse preparing 1400 gentamicin dose; reviewing case tabs before administration
Answer key & rationale
Frequently asked questions
What should I check before giving gentamicin?
Verify weight-based mg/kg dose with pharmacy, confirm allergies to aminoglycosides, review the latest basic metabolic panel and estimated glomerular filtration rate, check for concurrent nephrotoxic or ototoxic drugs (including loop diuretics), ensure IV gentamicin is appropriately diluted and not premixed with other drugs, and confirm whether a trough or peak level is due before the next dose per prescriber and pharmacy protocol.
When should nurses hold gentamicin?
Hold and contact the prescriber or pharmacist when creatinine or blood urea nitrogen rises sharply, urine output falls (oliguria), a trough level exceeds protocol limits (labeling warns against trough above 2 mcg/mL), the patient reports new tinnitus, hearing loss, or vertigo, there is known hypersensitivity to gentamicin or a serious reaction to another aminoglycoside, or renal function no longer supports the current interval without dose adjustment.
Why are peak and trough levels important for gentamicin?
Peak and trough sampling helps balance efficacy against toxicity. Labeling warns that prolonged peak concentrations above 12 mcg/mL and trough concentrations above 2 mcg/mL increase nephrotoxicity and ototoxicity risk. Nurses coordinate draw timing (typically trough within 30 minutes before the next dose per pharmacy protocol), document infusion completion times, and escalate out-of-range results to the prescriber or pharmacist for interval or dose adjustment.
Why is furosemide especially dangerous with gentamicin?
Both gentamicin and potent loop diuretics such as furosemide are nephrotoxic and ototoxic. The boxed warning directs avoidance of concurrent use when possible because combined renal injury and eighth cranial nerve damage are more likely—often irreversible. When both appear on the MAR, trend creatinine, blood urea nitrogen, urine output, and auditory symptoms closely and involve pharmacy early for level monitoring and dose-interval review.
Is there an antidote for gentamicin toxicity?
No specific antidote is listed in the reviewed prescribing information. Overdose or toxicity management is supportive: hold or adjust therapy with prescriber and pharmacy input, monitor renal function and fluid status, and hemodialysis may aid drug removal (approximately 50% removed in 8 hours per labeling). Contact local poison control or medical toxicology services per facility protocol for significant toxicity or instability.
References
- U.S. National Library of Medicine. GENTAMICIN SULFATE injection — Hospira SPL product labeling. DailyMed.https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=977180b3-a222-4282-d485-4a3217674305
- National Library of Medicine (US). Gentamicin. Drugs and Lactation Database (LactMed).https://www.ncbi.nlm.nih.gov/books/NBK500832/
- Joint Formulary Committee. Gentamicin monograph. BNF (NICE).https://bnf.nice.org.uk/drugs/gentamicin/
- U.S. Food and Drug Administration. Safety Tips for Injectable Medicines (STIC).https://www.fda.gov/STIC
- Institute for Safe Medication Practices. High-alert medications in acute care settings.https://www.ismp.org/recommendations/high-alert-medications-acute-list
Review and transparency
This medication guide is written and reviewed using NurseOnShift editorial and clinical review standards.
Educational use only. This content does not replace clinical judgment, prescriber orders, pharmacist guidance, product labeling, or institutional protocols.